465 N. HALSTEAD ST., PASADENA, CA
Reports First Quarter 2026 Financial Results
Investor Presentation
News, Material Contracts
Annual Report to Security Holders
Termination of Collaboration Agreement with Genentech, Inc.
Announces Change to Ultomiris® Royalty Revenue Forecast
Reports Fourth Quarter and Full Year 2025 Financial Results
Highlights Corporate Priorities and 2026 Pipeline Milestones
Q1
FY 2024
Q3
Q2
FY 2023
Amended Quarterly Report
Amended Annual Report
S-3ASR
Registration Statement for Securities to be Offered to Employees
Prospectus filed pursuant to Rule 424(b)(5)
Notice of Exempt Offering of Securities
Additional Proxy Materials
Definitive Proxy Statement
Amended Schedule 13G - Ownership Report
Statement of Changes in Beneficial Ownership
Notice of Proposed Sale of Securities
Schedule 13G - Ownership Report
S-8 POS